A new market research report by Transparency Market Research, titled “Multiple Sclerosis Drugs Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2012 - 2018”, covers a detailed evaluation of the market for multiple sclerosis drugs. The data collated in the report is a combination of historical information and insights from top industry leaders. Both primary as well as secondary research has been conducted for gathering information for this study.

Get Free Sample Research Report:
http://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=1130

A comprehensive review of the challenges, drivers, opportunities, and inhibitors acting on the market has been included under this study. In addition, information has also been provided on the regulatory environment in the market. The study also covers a number of products in phase III, II, and I of clinical trials and also elaborates on some key treatments used in the preclinical stages of disease development. The present status of the multiple sclerosis drugs along with the currently used vaccines and their predicted growth potential in the forecast period has also been presented in this report.

The report states that the market for the multiple sclerosis drugs is presently undergoing intense competition owing to the fact that a known cure for multiple sclerosis hasn’t been found yet. Currently, the market only comprises products utilized for curtailing the progress of multiple sclerosis. However, as per the report, the market is experiencing an exponential growth owing to the numerous cutting-edge product advancements and developments going on in the market. Industry giants such as Google Inc. have collaborated with Biogen Idec for the facilitation of various research and development activities to treat multiple sclerosis. On the other hand, the report states that factors such as strict regulations posed by governments and the lengthy process of drug approval may restrain the growth of the market in forthcoming years.

The report states that the market is led by the segment of injectables. On the other hand, the segment of oral drugs is also gaining popularity. Aubagio and Gilenya oral drugs are amongst the top 10 sellers in the market. In addition, Biogen’s oral BG-12 and Teva Laquinimod are the other two pipeline drugs predicted to be introduced in the market by 2017. However, as per the report, the segment of injectables will continue to grow, eclipsing the segment of oral multiple sclerosis drugs. This is owing to the rise in the awareness about the potentially fatal side effects, including heart diseases, associated with the usage of oral multiple sclerosis drugs.

Geographically, the report segments the market into Asia Pacific, North America, Europe, and Rest of the World (RoW). The report states that the major players in the market are GlaxoSmithKline, Bayer, Teva Pharmaceutical, Merck Serono, Novartis, Sanofi, Abbvie, Pfizer, Biogen Idec, Opexa, and AB Science, among others.

Full Research Report on Global Multiple Sclerosis Drugs Market: http://www.transparencymarketresearch.com/multiple-sclerosis-drugs.html